TLR2 and Niemann-Pick disease, type C1: Targeting α-synuclein and TLR2 may offer therapeutic potential for modifying neuroinflammation in PD and other conditions like Niemann–Pick disease type C1 (NPC1), multiple sclerosis, AD, and stroke [9,10,11].